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A 67-year-old male and never-smoker patient with unclassified 
deforming and symptomatic osteoarthritis (OA) of hands since 
2004 chronically treated with nonsteroidal anti-inflammatory 
drugs (diclofenac) was diagnosed in August 2010 of advanced 
lung adenocarcinoma T2 N3 M1a (pleural metastasis) with-
out initial molecular characterization. The patient was treated 
with six cycles of cisplatin and gemcitabine with a polyADP 
ribose polymerase (PARP) inhibitor/placebo as a part of a phase 
3 trial (NCT01082549), achieving a partial response in com-
puted tomography (CT) scan. In March 2012, CT scan showed 
pulmonary progression. At this time, the molecular tests were 
negative for oncogenic EGFR, KRAS, BRAF, HER2, or ALK-
rearrangement, and pemetrexed was initiated as second-line 
therapy. The patient only reported a temporary initial clinical 
improvement in OA symptoms with first-line and second-line 
chemotherapy treatment while receiving steroids as antiemetic 
therapy. In September 2013, after 17 cycles of pemetrexed, 
the CT scan reported bilateral pulmonary progression. A new 
pulmonary biopsy, on the basis of MOSCATO 01 protocol 
(NCT015566019), reported a ROS1-rearrangement by fluores-
cent in situ hybridization (FISH) in 40% of tumor cells. On the 
basis of these results, the patient started third-line treatment with 
off-label crizotinib 250 mg/twice daily. After 6 weeks on crizo-
tinib treatment, the patient showed a meaningful improvement 
in OA symptoms and dropped out of nonsteroidal anti-inflam-
matory treatment. After 16 months on crizotinib treatment, the 
patient is fully active without any evidence of disease progres-
sion neither recurrence of his OA symptomatology.
The introduction of targeted therapies based on recog-
nition of acquired genetic driver mutations has changed the 
treatment paradigm and improved survival for patients with 
advanced non–small-cell lung cancer (NSCLC).1 ROS1 rear-
rangements, a potent oncogenic driver, occur in 1% to 2% 
of patients with NSCLC. Crizotinib is a small-molecule oral 
inhibitor of ALK, c-MET (mesenchymal–epithelial transi-
tion)/hepatocyte growth factor (HGF) receptor, and ROS1 
receptor kinases, with a marked clinical activity in advanced 
and pretreated NSCLC ROS1-rearranged patients.2
OA is a chronic joint disorder characterized by progres-
sive articular cartilage degeneration, subcondral alteration, 
and variable synovial inflammation resulting in loss of joint 
function. The precise etiology and pathogenesis of OA remain 
largely unclear. However, recent evidence suggests that 
osteochondral angiogenesis is essential for the development 
and progression of OA and rheumatoid arthritis in humans.3 
Vascular endothelial growth factor (VEGF)-A is one of the 
most potent proangiogenic growth factors, and plasmatic 
and synovial fluid VEGF levels correlate with OA severity 
in humans.4 Moreover, treatment with an intravenous admin-
istration of a monoclonal antibody anti-VEGF significantly 
attenuates disease severity in OA rabbit models.5
HGF exhibits strong angiogenic properties through its 
ability to induce VEGF-A expression. The biological action of 
HGF is mediated through the proto-oncogene c-MET, a trans-
membrane tyrosine kinase cell surface receptor, expressed 
on a multitude of cells including chondrocytes, synovial 
fibroblasts, and endothelial cells. Stimulation of human 
OA synovial fibroblasts cells with HGF significantly 
induces concentration—and time-dependent increase in 
VEGF-A expression through c-MET pathway that triggers 
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FIGURE 1.  Schematic representation of HGF/c-MET pathway 
and HIF activity. HGF indicates hepatocyte growth factor; HRE, 
hypoxia response elements; HIF, hypoxia inducible factor.
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PI3K/Akt/mTOR activation. The hypoxia inducible factor 
(HIF) is a dominant regulator of VEGF-A expression. Nuclear 
translocation of HIF-1-alpha protein is necessary for its tran-
scriptional activation. HGF/cMET activation significantly 
enhances the stabilization and DNA binding activity of the 
HIF-1-alpha protein to the hypoxia response elements located 
in gene promoters known to regulate transcription of VEGF-A 
(Fig. 1). Moreover, pretreatment of OA synovial fibroblasts 
with a c-MET inhibitor or a HIF-1 inhibitor antagonizes HGF-
VEGF-A-dependent expression.6
To our knowledge, this is the first report of improve-
ment in OA symptoms with a MET inhibitor. Although an 
anti-VEGF antibody might be an attractive target for the OA 
therapy, their toxicity might limit their efficacy. Oral therapies 
such as MET inhibitors with better toxicity profiles and anti-
angiogenic effect might be of interest for testing in OA.
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